ZIVO Bioscience Initiates 42-Day Validation Study With Immune-Modulating Product For The Prevention And Treatment Of Coccidiosis In Broiler Chickens

Zivo Bioscience, Inc. (NASDAQ:ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces the initiation of a 42-day study to further validate the efficacy of its novel immune-modulating treatment for coccidiosis in broiler chickens.

ZIVO is developing a product candidate for use in poultry feed that is designed to boost immune response, allowing birds to effectively combat coccidiosis and reduce the negative effects of the disease without the use of antimicrobial compounds. The 42-day study is intended to confirm the previously-reported positive effects of ZIVO's non-antibiotic alternative for maintaining broiler health against a significant coccidiosis challenge, including reduced mortality and reduction in the incidence and severity of intestinal lesions that adversely affected bird growth rates and feed efficiency.

This new study will be performed under the same conditions as the previous 28-day coccidiosis challenge study, but will be carried out for the full 42-day grow out period typical in the broiler production industry. This study will also include analyses designed to verify previously observed secondary benefits of ZIVO's product that include protection or restoration of intestinal tissue morphology following exposure to the coccidiosis-causing Eimeria parasite, and reduction of pathogenic bacteria in a broiler chicken's gut that are responsible for food-borne illness in humans.

"Our coccidiosis product candidate holds potential to transform poultry health management. We are optimistic about this newest study given prior test results that substantiated the candidate's efficacy not only in mitigating or eradicating the detrimental impacts of coccidiosis on digestive health in broiler chickens, but also in aligning the cost per bird with that of traditional antibiotics and chemicals," said John Payne, Chairman and Chief Executive Officer of ZIVO Bioscience. "Furthermore, it has demonstrated a remarkable reduction in the prevalence of major foodborne pathogens such as Campylobacter, Salmonella, E. coli, and Clostridium perfringens in the broilers' digestive tract, without relying on antibiotics or other antimicrobial agents."

Mr. Payne added, "The factors we're examining in this study may have significant implications for human food safety during meat processing. With safeguards in place based on our learnings in prior exploratory studies, we expect data from this 42-day study will be pivotal and critical in potentially helping secure a partnership with a leading global animal health provider. We expect to report results from the study by the end of 2023."

Coccidiosis is a protozoal disease that causes diarrhea, weight loss, decreased performance and increased mortality in poultry. This disease represents a significant economic challenge for the global poultry industry, as indicated by a 2020 study that estimated annual costs ranging from $10 billion to $17 billioni. Products for treating coccidiosis are mostly antibiotic- or ionophore-based, and no significant new commercial technology has been introduced in the past 60 years. The global poultry industry spends more than $1.5 billion annually on coccidiosis control, primarily using decades-old compounds that industry and consumers alike wish to replace due to the risks of developing drug resistance. Coccidiosis is a common disease for chickens, especially among young chicks, and can be fatal or result in compromised digestion.